Sue Washer | CEO |
Matt Feinsod | EVP of Global Strategy and Development |
Mark Shearman | CSO |
Bill Sullivan | CFO |
Jim Birchenough | Wells Fargo |
David Nierengarten | Wedbush Securities |
Yun Zhong | Janney |
Zegbeh Jallah | ROTH Capital |
Emanuela Branchetti | H.C. Wainwright |
Good morning and welcome to the AGTC Third Quarter 2020 Financial Results Conference Call. Today's call is being recorded.
Before we get started, I would like to remind everyone that during the conference call, AGTC may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important risk factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in the Risk Factors section of AGTC's most recent filing -- filed annual report on Form 10-K and quarterly reports on Form 10-Q filed with the SEC. AGTC undertakes no obligation to update any forward-looking statements after the date of this call.